Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

Tuija Vaananen; Katriina Vuolteenaho; Hannu Kautiainen; Riina Nieminen; Timo Mottonen; Pekka Hannonen; Markku Korpela; Markku J. Kauppi; Kari Laiho; Oili Kaipiainen-Seppanen; Riitta Luosujarvi; Tea Uusitalo; Toini Uutela; Marjatta Leirisalo-Repo; Eeva Moilanen; NEO-RACo Study Grp

doi:10.1371/journal.pone.0183294

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

Tuija Vaananen, Katriina Vuolteenaho, Hannu Kautiainen, Riina Nieminen, Timo Mottonen, Pekka Hannonen, Markku Korpela, Markku J. Kauppi, Kari Laiho, Oili Kaipiainen-Seppanen, Riitta Luosujarvi, Tea Uusitalo, Toini Uutela, Marjatta Leirisalo-Repo, Eeva Moilanen, NEO-RACo Study Grp

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Artikelnummer	0183294
Tidskrift	PLoS One
Volym	12
Nummer	8
Antal sidor	15
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0183294
Status	Publicerad - 25 aug. 2017
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3121 Allmänmedicin, inre medicin och annan klinisk medicin
3111 Biomedicinska vetenskaper

Åtkomst av dokument

10.1371/journal.pone.0183294

Glycoprotein YKL-40Slutlig publicerad version, 2,91 MBLicens: CC BY

Citera det här

Vaananen, T., Vuolteenaho, K., Kautiainen, H., Nieminen, R., Mottonen, T., Hannonen, P., Korpela, M., Kauppi, M. J., Laiho, K., Kaipiainen-Seppanen, O., Luosujarvi, R., Uusitalo, T., Uutela, T., Leirisalo-Repo, M., Moilanen, E., & NEO-RACo Study Grp (2017). Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS One, 12(8), [0183294]. https://doi.org/10.1371/journal.pone.0183294

@article{5a11fb21fc254b2faa9a62eeae89cd96,

title = "Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial",

keywords = "HUMAN CARTILAGE GLYCOPROTEIN-39, SERUM YKL-40, RADIOGRAPHIC PROGRESSION, COMBINATION THERAPY, PERIPHERAL-BLOOD, ACTIVITY SCORES, FOLLOW-UP, MHC CLASS, JOINT, INFLAMMATION, 3121 General medicine, internal medicine and other clinical medicine, 3111 Biomedicine",

author = "Tuija Vaananen and Katriina Vuolteenaho and Hannu Kautiainen and Riina Nieminen and Timo Mottonen and Pekka Hannonen and Markku Korpela and Kauppi, {Markku J.} and Kari Laiho and Oili Kaipiainen-Seppanen and Riitta Luosujarvi and Tea Uusitalo and Toini Uutela and Marjatta Leirisalo-Repo and Eeva Moilanen and {NEO-RACo Study Grp}",

year = "2017",

month = aug,

day = "25",

doi = "10.1371/journal.pone.0183294",

language = "English",

volume = "12",

journal = "PLoS One",

issn = "1932-6203",

publisher = "PUBLIC LIBRARY OF SCIENCE",

number = "8",

}

Vaananen, T, Vuolteenaho, K, Kautiainen, H, Nieminen, R, Mottonen, T, Hannonen, P, Korpela, M, Kauppi, MJ , Laiho, K, Kaipiainen-Seppanen, O, Luosujarvi, R, Uusitalo, T, Uutela, T, Leirisalo-Repo, M, Moilanen, E & NEO-RACo Study Grp 2017, 'Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial', PLoS One, vol. 12, nr. 8, 0183294. https://doi.org/10.1371/journal.pone.0183294

Glycoprotein YKL-40 : A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. / Vaananen, Tuija; Vuolteenaho, Katriina; Kautiainen, Hannu et al.

I: PLoS One, Vol. 12, Nr. 8, 0183294, 25.08.2017.

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

TY - JOUR

T1 - Glycoprotein YKL-40

T2 - A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial

AU - Vaananen, Tuija

AU - Vuolteenaho, Katriina

AU - Kautiainen, Hannu

AU - Nieminen, Riina

AU - Mottonen, Timo

AU - Hannonen, Pekka

AU - Korpela, Markku

AU - Kauppi, Markku J.

AU - Laiho, Kari

AU - Kaipiainen-Seppanen, Oili

AU - Luosujarvi, Riitta

AU - Uusitalo, Tea

AU - Uutela, Toini

AU - Leirisalo-Repo, Marjatta

AU - Moilanen, Eeva

AU - NEO-RACo Study Grp

PY - 2017/8/25

Y1 - 2017/8/25

KW - HUMAN CARTILAGE GLYCOPROTEIN-39

KW - SERUM YKL-40

KW - RADIOGRAPHIC PROGRESSION

KW - COMBINATION THERAPY

KW - PERIPHERAL-BLOOD

KW - ACTIVITY SCORES

KW - FOLLOW-UP

KW - MHC CLASS

KW - JOINT

KW - INFLAMMATION

KW - 3121 General medicine, internal medicine and other clinical medicine

KW - 3111 Biomedicine

U2 - 10.1371/journal.pone.0183294

DO - 10.1371/journal.pone.0183294

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - 0183294

ER -